AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.
- Australian manufacturing transfer signed with Cell Therapies Pty Ltd
- BZDS1901 shows 20% complete tumour clearance in advanced mesothelioma
- Patient alive 22 months post-treatment with no tumour recurrence
- Manufacturing site to support global trials and commercial scale-up
- Target market for advanced mesothelioma estimated at US$4.2 billion
Rare Complete Responses Highlight BZDS1901 Potential
AdAlta’s lead CAR-T therapy, BZDS1901, has delivered remarkable clinical outcomes in advanced mesothelioma, including two patients achieving complete tumour clearance; a feat exceptionally rare in this aggressive cancer. One patient remains tumour-free and alive 22 months after treatment, underscoring the therapy’s promise in a disease where median survival after relapse typically falls below a year. These results come from early-stage clinical studies in China, where BZDS1901 has shown up to 50% overall tumour shrinkage and a 20% complete response rate, far exceeding current immunotherapy benchmarks.
Such data not only signal a potential breakthrough for relapsed mesothelioma patients but also position BZDS1901 as a contender in a market forecast to reach US$12.2 billion by 2034, with the advanced mesothelioma segment alone estimated at US$4.2 billion. The therapy’s potential extends beyond mesothelioma, with applicability in over ten other cancers under consideration.
Australian Manufacturing Transfer Marks Strategic Milestone
AdAlta has executed its first manufacturing Work Order with Cell Therapies Pty Ltd (CTPL) to transfer and optimise BZDS1901 production to Australia. This transfer is critical, as CAR-T therapies are patient-specific living drugs requiring precise, scalable manufacturing processes. The move enables planned Australian Phase 1 clinical trials and establishes a manufacturing hub that could serve as a global reference site for future multinational development and commercialisation.
CTPL’s two decades of experience in cell therapy manufacturing and its proximity to the Peter MacCallum Cancer Centre provide a strong foundation for process optimisation and regulatory compliance. Notably, BZDS1901’s manufacturing cycle is shorter and potentially less costly than traditional CAR-T products, taking just two days compared to the usual nine. This efficiency could enhance commercial viability and attractiveness to pharmaceutical partners.
The significance of manufacturing quality and scalability in CAR-T therapies cannot be overstated. As highlighted by AdAlta’s CEO, Dr Tim Oldham, manufacturing is inseparable from the product itself. The Australian transfer not only supports trial readiness but also materially strengthens BZDS1901’s licensing and partnering appeal, mitigating supply chain and regulatory risks often faced by cell therapy developers.
Advancing the ‘East to West’ Strategy with Manufacturing and Clinical Progress
AdAlta’s approach integrates promising Asian-developed therapies with Australia’s clinical and manufacturing expertise. The company is advancing two key value drivers for BZDS1901 simultaneously: generating compelling efficacy data and establishing a transferable, scalable manufacturing process. This dual progress is expected to enhance the program’s appeal to global oncology partners and accelerate regulatory pathways.
The manufacturing transfer follows recent progress in AdAlta’s collaboration with Shanghai Cell Therapy Group, which has supported clinical development and regulatory engagement. The company’s push to bring BZDS1901 manufacturing to Australia aligns with its broader strategy to scale solid cancer cell therapies efficiently, as evidenced by its recent IRO platform collaboration aimed at boosting production throughput and reducing costs.
These developments build on clinical momentum, with BZDS1901’s rare tumour disappearances reported earlier this year, doubling expected response rates in heavily pre-treated mesothelioma patients and paving the way for expanded trials in Western markets. The manufacturing transfer is a tangible step toward realising these ambitions and de-risks the pathway to commercialisation.
Bottom Line?
AdAlta’s manufacturing transfer to Australia is a pivotal step that could unlock clinical trial progress and enhance commercial partnerships, but the therapy’s broader success hinges on replicating early efficacy in larger, Western-based studies.
Questions in the middle?
- Will Australian clinical trials confirm BZDS1901’s rare complete response rates in a larger patient cohort?
- How quickly can manufacturing optimisations at CTPL be validated to support trial scale-up?
- What licensing or partnership deals might emerge as manufacturing and clinical milestones align?